The 3rd annual Immuno-Oncology 360° event, brought to you by Conference Forum, is taking place February 1-3, 2017 in NYC. Designed by lead Advisors Dr Axel Hoos (GSK) and Dr James Gulley (NCI) the program provides a unique 360-degree approach addressing the most-up-to-date information regarding business aspects, clinical advancements and scientific data that will help accelerate clinical trials and FDA approval, ultimately transforming the way cancer is treated.

With rapid development of cancer immunotherapy drug development, breakthrough FDA approval status, and fast-tracking clinical trials, competition is fierce. The science behind immune-based therapies is driving rapid change. Both small and large companies are racing to bring game-changing therapies to the market and in many cases, partnering to maximize on combination therapies. As a result, innovative approaches and developments are also creating increased momentum for investment/business development opportunities.